Application of next-generation sequencing technology to profile the circulating microRNAs in the serum of preeclampsia versus normal pregnant women.
Circulating miRNAs, as a new family of miRNAs existing in plasma and serum, had shown great potential to serve as a novel biomarker in body fluid for non-invasive diagnosis and prognosis of plenty kinds of disease, such as cancer and prenatal screening. In this present study, we analyzed the expression profiles of circulating miRNAs in the serum of four pregnant women with preeclampsia (PE) and one normal control of pregnant women, by the next generation sequencing technology. By annotated the raw sequence reads with the databases of miRNA, genome and others small RNA library, miRNA was found to be the major composition of those small RNA-annotated reads. In the result of circulating miRNA profiles in serum, up to 573 distinct miRNAs were annotated to miRBase. The biological features of circulating miRNA in serum were consistent with those tissue/cell based miRNA in the database. Notably, 22 miRNAs were found to be dys-regulated expressed with PE. Compared to the normal control, 15 and 7 miRNAs were up-regulated and down-regulated respectively in each four PE samples. Among these 22 miRNAs, 3 dys-regulated miRNAs have been reported to be dys-regulated in the placentas of PE pregnancies. Results showed that circulating miRNAs in serum of pregnant women could be detected more comprehensive by the next generation sequencing technology. It also suggested that those PE-related miRNAs obtained in this study might be used as notable biomarkers for diagnosis and prognosis of PE.